Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28302961 | 1.00 | HTR3A (0.53) | HTR3AESR2CYP2D6SLC6A2SLC6A4 | |
| Bromide SCHEMBL567414 | 0.98 | HTR3A (0.52) | HTR3AESR2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL20805968 | 0.90 | HTR3A (0.66) | HTR3AESR2 | |
| SCHEMBL25936803 | 0.86 | ESR2 (0.55) | ESR2CYP2D6ESR1CYP3A4CYP2C9 | |
| SCHEMBL23119873 | 0.81 | ESR2 (0.52) | HTR3AESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL1711100 | 0.80 | HTR3A (0.53) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25305280 | 0.80 | HTR3A (0.53) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13505492 | 0.80 | HTR3A (0.53) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16446546 | 0.80 | HTR3A (0.81) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24127465 | 0.80 | HTR3A (0.53) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810047-A | (R) synthetic method of the chiral intermediate of -3- Phenylpiperidine or/and (S) -3- Phenylpiperidine and Ni Lapani | 上海博邦医药科技有限公司 | 2019-05-28 | — | — | CN | claimed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| CN-109810047-A | (R) synthetic method of the chiral intermediate of -3- Phenylpiperidine or/and (S) -3- Phenylpiperidine and Ni Lapani | 上海博邦医药科技有限公司 | 2019-05-28 | — | — | CN | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-9850206-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850206-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850206-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2925721-B1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2925721-B1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2017-06-07 | — | — | EP | disclosed |
| CN-100349906-C | Phosphonoxyquinazoline derivatives and pharmaceutical use thereof | ASTRAZENECA AB (SE) | 2007-11-21 | — | — | CN | disclosed |
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| CN-1764668-A | Phosphonoxyquinazoline derivatives and pharmaceutical use thereof | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | CN | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| CN-1478092-A | Benzoxazinone derivatives, their preparation and use | ʷ | 2004-02-25 | — | — | CN | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
| CN-1029960-C | Process for preparing chromanol derivatives having neuroprotective effect | PFIZER (US) | 1995-10-11 | — | — | CN | disclosed |
| CN-1053923-A | 3-piperidino-(1-position only)-4-hydroxy benzo dichloro-pyran derivative with neuroprotective | PFIZER (US) | 1991-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | HTR3A 652/4885ESR2 1121/4885CYP2D6 9/4885 |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | HTR3A 611/4885ESR2 3/4885CYP2D6 235/4885 |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | HTR3A 611/4885ESR2 3/4885CYP2D6 235/4885 |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | HTR3A 611/4885ESR2 3/4885CYP2D6 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.